Investor Relations (IR) Questions: BioCryst Pharmacetuicals $BCRX
Click here to return to the biotech IRQ Index
Answers received: May 2013
1) When is the last time BCRX raised cash through an offering (diluted)?
In November 2009, we sold 5 million shares at an offering price of $9.75.
Our S-3 is active and the ATM vehicle attached to it is a functioning means to sell BCRX at market prices at any time, assuming there is no regulatory restriction precluding a sale.
We did use the ATM in the fourth quarter of 2011 for the first time since its inception in June/July 2011, and at various times over the last five quarters. During 1Q13, we sold an insignificant number of shares.
2) How much cash (not cash equivalents) does BCRX have?
$14.8 million as of 3/31/13
$28.3 million of cash, cash equivalents & investments as of 3/31/13
3) What and approximately when is the next known catalyst?
· Complete BCX4161 Phase 1 trial & report outcome (summer:13)
· Publish filovirus infection animal model POC data for BCX4430 (mid:13)
· Initiate BCX4161 study in HAE patients (2H:13)
· Advance optimized second generation HAE lead into preclinical development (2013)
· Peramivir NDA filing (late 2013/early 2014)
4) What is BCRX's quarterly cash burn?
Our outlook for FY13 is operating cash use of $22-26 million.
Operating cash use excludes any impact of our royalty monetization, hedge collateral posted or returned, sale of stock in the marketplace, and any other non-routine cash outflows or inflows, like restructuring and transaction costs
5) Does BCRX have an existing line of credit and if so how much can they draw against it?
BCRX does not have an existing line of credit
Regards,
Robert Bennett
Executive Director, Investor Relations & Operations
BioCryst Pharmaceuticals, Inc
1) When is the last time BCRX raised cash through an offering (diluted)?
In November 2009, we sold 5 million shares at an offering price of $9.75.
Our S-3 is active and the ATM vehicle attached to it is a functioning means to sell BCRX at market prices at any time, assuming there is no regulatory restriction precluding a sale.
We did use the ATM in the fourth quarter of 2011 for the first time since its inception in June/July 2011, and at various times over the last five quarters. During 1Q13, we sold an insignificant number of shares.
2) How much cash (not cash equivalents) does BCRX have?
$14.8 million as of 3/31/13
$28.3 million of cash, cash equivalents & investments as of 3/31/13
3) What and approximately when is the next known catalyst?
· Complete BCX4161 Phase 1 trial & report outcome (summer:13)
· Publish filovirus infection animal model POC data for BCX4430 (mid:13)
· Initiate BCX4161 study in HAE patients (2H:13)
· Advance optimized second generation HAE lead into preclinical development (2013)
· Peramivir NDA filing (late 2013/early 2014)
4) What is BCRX's quarterly cash burn?
Our outlook for FY13 is operating cash use of $22-26 million.
Operating cash use excludes any impact of our royalty monetization, hedge collateral posted or returned, sale of stock in the marketplace, and any other non-routine cash outflows or inflows, like restructuring and transaction costs
5) Does BCRX have an existing line of credit and if so how much can they draw against it?
BCRX does not have an existing line of credit
Regards,
Robert Bennett
Executive Director, Investor Relations & Operations
BioCryst Pharmaceuticals, Inc
Answers received: September 2012
1) When is the last time BCRX raised cash through an offering (diluted)?
Last equity financing was November 2009. Press release link: http://investor.shareholder.com/biocryst/releasedetail.cfm?ReleaseID=425634
During the first six months of 2012, we had an active at the marketing program that provided $16.8m in cash, offsetting most of our operating cash demands for the period.
2) How much cash (not cash equivalents) does BCRX have?
On June 30, we had $21.4m in cash, and $53.5m in cash, equivalents and investments
3) What and approximately when is the next known catalyst?
Expected catalysts and progress to date are summarized on slide #17 at the link below (under question 4)
4) What is BCRX's quarterly cash burn?
Operating cash outlook for 2012 forecast in the range of $37-$43m (excludes any inbound proceeds) See slide #6 at the link below
http://files.shareholder.com/downloads/BCRX/2077386182x0x587853/f40d0fcd-37de-4742-bcca-5d43d2806b59/BCRX%20Q2%202012%20slides%202Aug12%20FINAL.pdf
5) Does BCRX have an existing line of credit and if so how much can they draw against it?
We do not have a line of credit for funding operations.
1) When is the last time BCRX raised cash through an offering (diluted)?
Last equity financing was November 2009. Press release link: http://investor.shareholder.com/biocryst/releasedetail.cfm?ReleaseID=425634
During the first six months of 2012, we had an active at the marketing program that provided $16.8m in cash, offsetting most of our operating cash demands for the period.
2) How much cash (not cash equivalents) does BCRX have?
On June 30, we had $21.4m in cash, and $53.5m in cash, equivalents and investments
3) What and approximately when is the next known catalyst?
Expected catalysts and progress to date are summarized on slide #17 at the link below (under question 4)
4) What is BCRX's quarterly cash burn?
Operating cash outlook for 2012 forecast in the range of $37-$43m (excludes any inbound proceeds) See slide #6 at the link below
http://files.shareholder.com/downloads/BCRX/2077386182x0x587853/f40d0fcd-37de-4742-bcca-5d43d2806b59/BCRX%20Q2%202012%20slides%202Aug12%20FINAL.pdf
5) Does BCRX have an existing line of credit and if so how much can they draw against it?
We do not have a line of credit for funding operations.